AR and prostate cancer: Wang et al12 use a comprehensive review of prostate cancer genetics listing 33 of the commonest genetic alterations with their biological function to highlight emerging targeted therapies and immunotherapies, including apalutamide (an AR antagonist), atrasentan (antagonist of the endothelin receptor), and denosumab (RANKL targeting monoclonal antibody) as well as PCa vaccines and checkpoint inhibitors, respectively.